← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBHotBiologicstaleRochePhase 2

Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 100%임상시험 108상태 ACTIVE
ADCBHotBiologicstaleDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 69.7%임상시험 107상태 ACTIVE
ADCCHotBiologicstaleRochePhase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 100%임상시험 106상태 DISCONTINUED
AntibodyBHotstaleBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
ADCCHotBiologicstaleHoffmann-La RochePhase 2

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 31%임상시험 104상태 RECRUITING
AntibodyCHotstaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyCstalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#인기#항체+5
임상시험 97상태 RECRUITING
ADCCBiologicstaleEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 40%임상시험 97상태 RECRUITING
CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 77.3%임상시험 96상태 RECRUITING
AntibodyBstaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#인기#항체+4
효능 ORR 53%임상시험 95상태 ACTIVE
ADCBBiologicstaleGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 34.3%임상시험 94상태 RECRUITING
ADCABiologicstaleAstraZenecaPhase 2

5-FU (Fluorouracil, Fluorouracil (5-FU))

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 63.5%임상시험 93상태 RECRUITING
ADCABiologicstaleAmgenPhase 3

Pegfilgrastim (Pegfilgrastim)

Cancer; Colon Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 56.7%임상시험 93상태 RECRUITING
AntibodyCstaleJunshi Biosciencesvedotin (EV) in combination…Phase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#인기#항체+5
임상시험 93상태 RECRUITING
ADCBBiologicstaleJiangsu Simcere Pharmaceutical …Phase 3

Palbociclib (Palbociclib)

Head and Neck Squamous Cell Carcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 79.5%임상시험 92상태 DISCONTINUED
ADCABiologicstaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 91상태 RECRUITING
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
ADCBBiologicstaleBayerPhase 3

Regorafenib (Regorafenib)

Metastatic Colorectal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 54%임상시험 90상태 RECRUITING
ADCCBiologicstaleCelgenePhase 2

5-Azacytidine (5-Azacytidine)

Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 75%임상시험 89상태 DISCONTINUED
ADCCBiologicstaleAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 59%임상시험 89상태 DISCONTINUED

5 / 177 페이지

← 이전다음 →